AtriCure (ATRC)

• Market cap: $1.57B
• 1 day: -0.84%
• 5 days: -3.23%
• 1 month: -5.37%
• 3 months: -19.91%
• 6 months: 11.21%
• Year to date: 4.41%
• 1 year: 39.76%
• 5 years: -20.65%
• 10 years: 46.47%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Employees: 1,300

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

806% more call options, than puts

Call options by funds: $1.25M | Put options by funds: $138K

74% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 23

7% more funds holding

Funds holding: 198 [Q3] → 211 (+13) [Q4]

3% more capital invested

Capital invested by funds: $1.38B [Q3] → $1.42B (+$40.9M) [Q4]

3% less repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 71

5.57% less ownership

Funds ownership: 100.93% [Q3] → 95.36% (-5.57%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 42% upside
• Avg. target: $52 62% upside
• High target: $60 89% upside

8 analyst ratings

• positive: 8 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Daniel Stauder 9% 1-year accuracy 1 / 11 met price target	89% upside $60	Market Outperform Reiterated	2 Apr 2025
Canaccord Genuity William Plovanic 37% 1-year accuracy 18 / 49 met price target	64% upside $52	Buy Maintained	28 Mar 2025
JP Morgan Lilia-Celine Lozada 33% 1-year accuracy 1 / 3 met price target	45% upside $46	Overweight Maintained	27 Mar 2025
Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target	61% upside $51	Buy Reiterated	27 Mar 2025
Oppenheimer Suraj Kalia 43% 1-year accuracy 9 / 21 met price target	42% upside $45	Outperform Maintained	13 Feb 2025